vaccines

J&J, BARDA join forces to prep for pandemic flu, inking deal for vaccine and drug R&D
J&J, BARDA join forces to prep for pandemic flu, inking deal for vaccine and drug R&D
Fierce Pharma
JNJ
BARDA
pandemic flu
vaccines
R&D
Flag link:
GSK lines up a shot at a blockbuster market as new CEO prepares to tackle Merck rival head on
GSK lines up a shot at a blockbuster market as new CEO prepares to tackle Merck rival head on
Endpoints
GSK
Pharma CEOs
Emma Walmsley
vaccines
Shingrix
Zostavax
shingles
Flag link:
Prevnar 13 among blockbusters industry watchers peg as tribal licensing candidates
Prevnar 13 among blockbusters industry watchers peg as tribal licensing candidates
Fierce Pharma
Prevnar 13
vaccines
licensing
Pfizer
Flag link:
Families sending kids to college get mixed messages on meningitis B vaccine
Families sending kids to college get mixed messages on meningitis B vaccine
Stat
meningitis B
vaccines
Trumenba
Bexsero
Flag link:
Sanofi quietly pulls the plug on its Zika vaccine project
Sanofi quietly pulls the plug on its Zika vaccine project
Stat
Sanofi
Zika virus
vaccines
Flag link:
Sanofi pulls out of Zika vaccine collaboration as feds gut its R&D contract
Sanofi pulls out of Zika vaccine collaboration as feds gut its R&D contract
Fierce Pharma
Sanofi
Zika virus
vaccines
R&D
government contracts
Flag link:
HPV vaccination rates ticking upward, CDC says as it urges more uptake
HPV vaccination rates ticking upward, CDC says as it urges more uptake
Fierce Pharma
vaccines
HPV
CDC
Merck
Gardasil
Flag link:
Top 25 vaccine products in 2016, based on U.S. sales
Top 25 vaccine products in 2016, based on U.S. sales
Medical Marketing and Media
vaccines
Pfizer
Merck
Sanofi
Prevnar 13
Gardasil
Fluzone
Varivax
Menactra
Flag link:
Why Sanofi's dengue fever vaccine fell short of expectations
Why Sanofi's dengue fever vaccine fell short of expectations
Medical Marketing and Media
Sanofi
vaccines
dengue
Dengvaxia
Flag link:
A Serious Reaction After Vaccination Rarely Occurs Again With Later Immunization
A Serious Reaction After Vaccination Rarely Occurs Again With Later Immunization
Forbes
vaccines
allergic reaction
side effects
adverse events
Flag link:
Peter Thiel funds offshore test of herpes vaccine, evading U.S. safety regulations
Peter Thiel funds offshore test of herpes vaccine, evading U.S. safety regulations
Stat
Peter Thiel
vaccines
herpes
clinical trials
Flag link:
Upcoming events – GSK’s shingles panel and Axovant takes on Alzheimer’s
Upcoming events – GSK’s shingles panel and Axovant takes on Alzheimer’s
EP Vantage
GSK
shingles
vaccines
Shingrix
Axovant
Alzheimer's disease
intepirdine
Flag link:
Nanotech, immunotherapy combo vaccinates mouse against cancer
Nanotech, immunotherapy combo vaccinates mouse against cancer
Drug Delivery Business News
nanotech
immunotherapy
vaccines
cancer
Flag link:
Dynavax shares dip after FDA asks for more time to sort out Heplisav post-marketing plan
Dynavax shares dip after FDA asks for more time to sort out Heplisav post-marketing plan
Endpoints
Dynavax
FDA
Heplisav
vaccines
hepatitis B
Flag link:
Vaccines provide a boost for GlaxoSmithKline, Sanofi and Merck in second-quarter financials
Vaccines provide a boost for GlaxoSmithKline, Sanofi and Merck in second-quarter financials
Fierce Pharma
vaccines
GSK
Sanofi
Merck
earnings
Flag link:
Data supports safety of Dynavax hepatitis B vaccine -U.S. FDA panel
Data supports safety of Dynavax hepatitis B vaccine -U.S. FDA panel
Yahoo/Reuters
Dynavax
vaccines
hepatitis B
Heplisav
FDA
advisory panels
Flag link:
J&J inks $879M vaccine deal with Bavarian Nordic
J&J inks $879M vaccine deal with Bavarian Nordic
BioPharma Dive
JNJ
vaccines
Bavarian Nordic
Janssen
hepatitis B
Flag link:
Dynavax shares slide as FDA review spotlights a hazy safety issue for Heplisav
Dynavax shares slide as FDA review spotlights a hazy safety issue for Heplisav
Endpoints
Dynavax
FDA
Heplisav
hepatitis B
vaccines
Flag link:
Provention Bio wants to stop Type I diabetes – with a vaccine
Provention Bio wants to stop Type I diabetes – with a vaccine
Drug Delivery Business News
Provention Bio
type 1 diabetes
vaccines
Flag link:
Novavax makes a case for a do-over on its failed RSV vaccine — but it’s an uphill climb
Novavax makes a case for a do-over on its failed RSV vaccine — but it’s an uphill climb
Endpoints
Novavax
vaccines
RSV
RSV F vaccine
Flag link: